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Abstract  (295 words) 
 
Background. Chronic obstructive pulmonary disease (COPD) often coexists with 
cardiovascular disease. Treatments for airflow limitation may improve survival and both 
respiratory and cardiovascular outcomes.  
Methods. In a double-blind randomised controlled trial, 16,485 patients with symptomatic 
moderate COPD and heightened cardiovascular risk received once daily inhaled placebo, 
fluticasone furoate (100 μg), vilanterol (25 μg) or the combination. Primary outcome was all-
cause mortality, and secondary outcomes were on-treatment rate of decline in forced 
expiratory volume in one second (FEV1) and composite of cardiovascular events.  
Findings. Compared with placebo, all-cause mortality was unaffected by combination 
therapy (hazard ratio (HR) 0·878, [95% confidence interval 0·739 to 1·042]; 12·2% relative 
reduction; P=0·137) or the components (fluticasone furoate, HR 0·911 [0·767 to 1·081]; 
vilanterol, HR 0·962 [0·813 to 1·139]), and therefore secondary outcomes should be 
interpreted with caution. Rate of decline in FEV1 was reduced by combination therapy (38 
versus 46 mL/year for placebo, difference 8 mL/year [1 to 15]) with similar findings for 
fluticasone furoate (difference 8 mL/year [1 to 14]) but not vilanterol (difference -2 mL/year 
[-8 to 5]). Combination therapy had no effect on composite cardiovascular events (HR 0·926 
[0·750 to 1·143]) with similar findings for fluticasone furoate (HR 0·896 [0·723 to 1·111]) 
and vilanterol (HR 0·988 [0·802 to 1·217]). All treatments reduced the rate of moderate and 
severe exacerbations. There were no reported excess risks of pneumonia or adverse cardiac 
events in the treatment groups. 
Interpretation. In patients with moderate COPD and heightened cardiovascular risk, 
treatment with fluticasone furoate and vilanterol did not affect mortality or cardiovascular 
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outcomes, reduced exacerbations and was well tolerated. Fluticasone furoate, alone or in 
combination with vilanterol, appeared to reduce FEV1 decline. 
Funding. The study was funded by GlaxoSmithKline. 
 
 
Keywords:  COPD; cardiovascular disease; mortality; survival; fluticasone furoate; 
vilanterol; combination therapy, rate of decline of FEV1. 
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Research in context 
Evidence before this study 
Up to November 2015, we searched PubMed and ClinicalTrials.gov for published or on 
going studies that examined the treatment of patients with concomitant chronic obstructive 
pulmonary disease (COPD) and cardiovascular disease (CVD) with inhaled corticosteroids or 
long-acting beta-agonists with the following search terms: “COPD”, “cardiovascular 
disease”, “inhaled corticosteroids”, “long-acting beta-agonists”. The search also used our 
familiarity with the medical literature and research in progress within the specialty. There 
were no adequately powered trials, and only a limited number of post-hoc or subgroup 
analyses of larger trials, to provide clinicians with evidence to make decisions about the 
treatment of patients with concomitant COPD and CVD. 
Added value of this study 
Our findings bridge a crucial gap by providing clinicians with evidence regarding inhaled 
treatments for patients with concomitant moderate COPD and CVD. In this patient group, 
combined inhaled corticosteroid and long-acting beta-agonist treatment had no effect on 
overall mortality or cardiovascular events. In contrast to inhaled beta-agonist therapy, inhaled 
corticosteroid treatment was associated with a reduction in the rate of decline of lung 
function. All treatments reduced the rate of moderate and severe exacerbations. 
Implications of all of the available evidence 
Treatment with a combination of an inhaled corticosteroid and long-acting beta-agonist has 
documented benefits in COPD. In patients with moderate COPD and CVD, these benefits do 
not extend to reductions in overall mortality or cardiovascular events. However, inhaled 
corticosteroid therapy does appear to inhibit the rate of decline in lung function.  
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Introduction 
Chronic obstructive pulmonary disease (COPD) often coexists with other chronic diseases 
that can contribute to patients’ health status and prognosis (1-3). Impaired pulmonary 
function is particularly associated with cardiovascular morbidity and mortality, and patients 
with COPD are at greater risk of cardiovascular disease compared with age and sex-matched 
individuals without COPD (4-7). Furthermore, more patients with moderate airflow 
limitation die from cardiovascular disease and lung cancer than from the respiratory 
consequences of COPD (8, 9). Several mechanisms have been proposed to link COPD with 
the increased risk of cardiovascular disease including shared risk factors (e.g., smoking), 
systemic inflammation (10), vascular dysfunction (11) and sedentary activity secondary to 
the functional consequences of COPD (12). Conversely, treatments that improve lung 
function and reduce exacerbations would be anticipated to reduce these factors thereby 
improving both respiratory and cardiovascular outcomes (13). 
 
The current Global Initiative for Chronic Obstructive Lung Diseases (GOLD) strategy 
document has highlighted the need to assess and treat comorbidities in COPD (1). However, 
the evidence base is incomplete and most advice comes from expert statements or from 
secondary analyses of large studies. Indeed, there is disagreement on the potential effects of 
COPD treatment on cardiovascular outcomes. Some evidence suggests that in patients with 
COPD, inhaled beta-agonist therapy may be associated with adverse cardiovascular outcomes 
(14). On the other hand, in secondary analyses of the TOwards a Revolution in COPD Health 
(TORCH) trial (15), there were apparent reductions in respiratory and cardiovascular 
mortality with inhaled salmeterol and fluticasone propionate. This was the rationale for the 
current trial where we address the hypothesis that inhaled corticosteroid and long-acting beta-
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agonist therapy could improve mortality in patients with both COPD and cardiovascular 
disease. 
 
In the Study to Understand Mortality and MorbidITy (SUMMIT), we prospectively assessed 
whether inhaled treatment with the corticosteroid, fluticasone furoate, and the long-acting 
beta-agonist, vilanterol, would improve survival compared with placebo in patients with 
moderate COPD and heightened cardiovascular risk.  
.  
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Methods 
Details of the study design and the analysis approach were published previously (13). 
 
Patients 
Between 24th January 2011 and 12th March 2014, we recruited patients who were current or 
former smokers with at least a 10-pack-year history. Eligible patients were 40 to 80 years old, 
diagnosed with COPD and had a post-bronchodilator forced expiratory volume in one second 
(FEV1) ≥50 and ≤70% of the predicted value (16), ratio of post-bronchodilator FEV1 to 
forced vital capacity (FVC) ≤0·70, and ≥2 on the modified Medical Research Council 
dyspnoea scale. Patients had to have a history, or be at increased risk, of cardiovascular 
disease. Cardiovascular disease was defined as coronary artery disease, peripheral arterial 
disease, stroke, myocardial infarction or diabetes mellitus with target organ disease. 
Increased cardiovascular risk was defined as ≥60 years and receiving medication for ≥2 of the 
following: hypercholesterolaemia, hypertension, diabetes mellitus or peripheral arterial 
disease. Exclusion criteria included respiratory disorders other than COPD, lung reduction 
surgery, receiving long-term oxygen or oral corticosteroid therapy, severe heart failure (New 
York Heart Association Class IV or ejection fraction <30%), life expectancy <3 years, and 
end-stage chronic renal disease (13). All patients provided written informed consent. The 
study was approved by local ethics committees and was conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice guidelines. The study is registered on 
clinicaltrials.gov as NCT01313676. 
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Study Design 
This was a prospective double blind parallel group placebo controlled event-driven 
randomised trial conducted at 1,368 centres in 43 countries. Participants were allocated 
equally to one of four treatments (placebo, fluticasone furoate (100 μg; GlaxoSmithKline), 
vilanterol (25 µg; GlaxoSmithKline) or the combination of fluticasone furoate and vilanterol 
(100/25 μg; Relvar®/Breo®, GlaxoSmithKline)) administered once daily as a dry powder with 
the use of an inhaler (Ellipta®, GlaxoSmithKline).  
 
The use of all inhaled corticosteroids and inhaled long-acting bronchodilators was 
discontinued at least 48 hours before study entry, although other COPD medications such as 
theophyllines were permitted (13). Patients unable to tolerate withdrawal of therapy were 
excluded from study entry. After randomisation, patients were seen every 3 months to 
confirm vital status and record adverse events. Post-bronchodilator spirometry was performed 
every 3 months and health status was assessed at 3 months then every 6 months. An 
independent data monitoring committee (IDMC) performed safety reviews every 6 months, 
and one pre-defined interim efficacy analysis was performed after a total of approximately 
500 deaths had occurred. The stopping guideline for efficacy was the Haybittle-Peto method 
(one-sided P value of 0·00005) in order to have a negligible impact on the final significance 
level. 
 
Randomisation and masking 
Participants were randomly assigned through a centralised randomisation service in permuted 
blocks. The randomisation schedule was generated using the GSK validated randomisation 
software RANDALL. A separate randomisation schedule was produced for each country. 
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Treatment was double blind (masking was achieved with Ellipta® inhalers of identical 
appearance) with only the database administrators having knowledge of treatment 
assignment. 
 
Outcome Measurements 
The primary efficacy outcome was the time to death from any cause, regardless of 
maintenance of study medication. Categorisation of cause of death was performed by a 
clinical end-point committee using all available information including study data, death 
certificates, autopsy findings, and health records (17). Secondary end-points were on-
treatment rates of decline in FEV1 and the on-treatment composite cardiovascular end-point 
of cardiovascular death, myocardial infarction, stroke, unstable angina and transient 
ischaemic attack. Exacerbations were an additional outcome. Moderate exacerbations were 
defined as a symptomatic deterioration requiring treatment with antibiotic agents and/or 
systemic corticosteroids, whereas severe exacerbations were defined as events leading to 
hospital admission. 
 
Safety Evaluation 
Adverse events and medications were reviewed at each study visit. All terms that could relate 
to a specific adverse event were compiled to provide a more comprehensive assessment of a 
specific safety term. The IDMC oversaw the ethical and safety interests of the patients by 
periodically reviewing cumulative data on serious adverse events in addition to the interim 
analysis. 
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Statistical Analysis 
This was an event-driven study where follow up continued until at least 1,000 deaths had 
occurred. All data analysis decisions were determined prior to unblinding. To ensure no bias 
in the ascertainment of survival status, a “common end date” was determined several months 
in advance. This common end date was selected so that there would be at least 1,000 deaths 
by this date.  The common end-date was set at 25 January 2015, and sites were required to 
ascertain the survival status of their patients on or after this date.   
 
We assumed an annual placebo event rate of 3.0% per year (13, 15) and the study was 
designed to have 90% power to detect a 30% reduction in all-cause mortality (hazard 
ratio=0·70) on combination therapy compared with placebo at the two-sided 1% significance 
level (13). Statistical significance was taken as two-sided P<0·05. To control for multiplicity 
of testing of combination treatment versus placebo across endpoints, a closed testing 
procedure (“gatekeeper”) approach was planned. The hierarchy was the primary endpoint 
followed by the rate of decline in FEV1 followed by the composite cardiovascular endpoint.  
If significance at the 5% level was not achieved for the primary endpoint for the comparison 
of combination treatment with placebo, then the tests for the secondary and other efficacy 
endpoints would be interpreted as descriptive only. The primary efficacy endpoint was 
analysed using a Cox proportional hazards regression model allowing for covariates of age 
and sex. A similar model was used for the time to the first on-treatment composite 
cardiovascular event, with the inclusion of two additional covariates: the presence of 
ischemic heart disease (e.g. previous MI) or vascular disease (e.g. previous stroke) at 
baseline. The rate of decline was analysed using a random coefficients model allowing for 
covariates of age, sex and baseline FEV1. The slope was calculated from 90 days, to ensure 
that any initial short term increase in FEV1 did not overestimate any treatment benefit on the 
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slope. The frequency of exacerbations was analysed with the use of a generalized linear 
model (assuming a negative binomial distribution, which accounts for variability among 
patients in the number and frequency of exacerbations), with the number of exacerbations as 
the outcome and the logarithm of time during which treatment was received as an offset 
variable. Adverse events of special interest were compared between treatment groups using 
Kaplan-Meier estimates.   
 
Scientific oversight of the trial was provided by a scientific steering committee composed of 
six academic researchers and three employees from GlaxoSmithKline, who were collectively 
responsible for the study design and conduct, for approval of the statistical analysis plan, and 
for the review and interpretation of the data.  
 
Role of the funding source 
The study was designed by the sponsor in collaboration with the academic members of the 
steering committee. The sponsor was responsible for the running of the trial, data collection, 
and statistical analysis. Statistical analyses were performed by a contract research 
organisation on behalf of, and with oversight from, employees of the sponsor. The first draft 
of the manuscript was written by the primary academic author, and all the authors worked 
collaboratively to prepare the final content. All authors made the decision to submit the 
manuscript for publication. All the authors had full access to the data and vouch for the 
accuracy and completeness of all data and analyses, and for the fidelity of the study to the 
protocol. The corresponding author had access to all the data and had final responsibility for 
the decision to submit for publication. 
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Results 
Study Population 
Of 23,835 patients screened, 16,590 underwent randomisation (Figure 1). Of these, 22 
subjects never took study medication and the safety population therefore consists of 16,568 
patients. Data from 5 centres (83 patients) were excluded from the efficacy analysis because 
of failure to meet the standards of Good Clinical Practice and ethical practice, and were 
closed before the study ended. Thus, a total of 16,485 patients were included in the intent-to-
treat efficacy (ITT) population (Table 1).  
 
Approximately one-third of patients stopped inhaled corticosteroids prior to study entry, with 
a similar proportion stopping long-acting beta-agonists. Thirty nine percent of patients 
reported having had a COPD exacerbation in the year before entry. A subset of 27% of 
patients who completed questionnaires were symptomatic with mean baseline scores of 45-46 
across all treatment groups on the St. George’s Respiratory Questionnaire (SGRQ) scale, and 
18-19 on the COPD Assessment Test (CAT). Three-quarters of patients had established 
cardiovascular disease or diabetes mellitus with end-organ disease (n=11,662, 71%), while a 
quarter (n=4,641, 28%) had an increased risk of cardiovascular disease only. Blood pressure 
at entry was on average ~135/80 mmHg across all treatment groups. There were 182 patients 
who failed to meet the cardiovascular entry criteria but were included in all analyses. More 
patients withdrew from study medication in the placebo group (29%) than in the three other 
groups: the lowest withdrawal rates were seen with combination therapy (23%).  The 
maximum follow-up was 4 years; median study exposure was 1·8 years and was similar 
across all treatment arms, with an interquartile range of 1·2 to 2·6 years. Treatment exposure 
was highest with combination therapy followed by vilanterol, fluticasone furoate and then 
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placebo (Table 2). The rate of adherence to treatment was similar in all groups with only 494 
patients (3%) taking <80% of prescribed study medication doses. 
 
Mortality 
Vital status was known for 16,480 (99·97%) of the 16,485 patients in the ITT population. At 
the common end date there were 1,037 deaths: 24 deaths occurred after the common end date 
with 10 still receiving study medication. The proportions of deaths from any cause were 
6·7% in the placebo group, 6·1% in the fluticasone furoate group, 6·4% in the vilanterol 
group, and 6·0% in the combination therapy group. Compared with placebo, the absolute risk 
reduction for death with combination therapy was 0·7%: a hazard ratio of 0·878 (95% 
confidence interval [CI], 0·739 to 1·042; P=0·137) corresponding to a relative reduction of 
12·2% (95% CI, -4·2 to 26·1%; Figure 2). There was no significant heterogeneity according 
to age, sex, baseline therapy or presence of cardiovascular disease. The risk of death in the 
fluticasone furoate group and the vilanterol group did not differ from the placebo group 
(Table 3). Overall, 43% of deaths were adjudicated as due to cardiovascular causes, 23% to 
cancer, and 13% to pulmonary causes (Table 3). 
 
Secondary outcomes 
On-treatment rates of FEV1 decline were 46 mL per year in the placebo group, 38 mL per 
year in the fluticasone furoate group (difference from placebo 8 mL per year, 95% confidence 
interval, 1 to 14 mL per year), 47 mL per year in the vilanterol group (difference from 
placebo -2 mL per year, -8 to 5 mL per year) and 38 mL per year in the combination 
treatment group (difference from placebo 8 mL per year, 1 to 15 mL per year) (Figure 3 and 
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Table 3). As combination treatment did not reduce overall mortality (the primary outcome) 
statistical inferences from these findings cannot be made. 
 
The proportions of patients with an on-treatment composite cardiovascular end-point were 
4·2% in the placebo group, 3·9% in the fluticasone furoate group, 4·4% in the vilanterol 
group and 4·2% in the combination therapy group (Table 3). Compared with placebo, 
combination therapy had no effect on the composite cardiovascular endpoint (HR 0·926, 95% 
confidence interval 0·750 to 1·143). Similarly, the composite cardiovascular end-point in the 
fluticasone furoate (HR 0·896, 0·723 to 1·111) and vilanterol (HR 0·988, 0·802 to 1·217) 
groups did not differ from placebo. 
 
Exacerbations 
Compared with placebo, the percent reduction in moderate and severe exacerbations was 
12% (95% confidence interval 4%-19%) for the fluticasone furoate group, 10% (2%-18%) 
for the vilanterol group, and 29% (22%-35%) for the combination group (Table 3). For 
exacerbations requiring hospital admissions the percent reduction was 18% (3%-31%) for the 
fluticasone furoate group, 20% (5%-32%) for the vilanterol group, and 27% (13%-39%) for 
the combination group, compared with placebo. As with FEV1 decline, these findings can 
only be viewed descriptively as combination treatment did not reduce overall mortality (the 
primary outcome). 
 
Safety 
Adverse events were reported by 68% of the patients in the study, and serious adverse events 
were reported by 23% of the patients. The most frequently reported adverse event was an 
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exacerbation of COPD. There was no excess of pneumonia, cardiac disorders or arrhythmias 
across all treatment groups. There were no differences in the incidence of fractures or eye 
disorders whereas more patients allocated to fluticasone furoate experienced local steroid 
effects (oral candidiasis and hoarseness) (Table 2).  
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Discussion 
SUMMIT is the largest survival study to date of an inhaled corticosteroid and long-acting 
beta-agonist in patients with COPD and heightened cardiovascular risk. In over 16,000 
patients, treatment with inhaled fluticasone furoate and vilanterol had no significant effect on 
all-cause mortality or cardiovascular outcomes. Inhaled therapy improved lung function and 
fluticasone furoate, alone or in combination with vilanterol, was associated with a reduction 
in the rate of decline in FEV1. We conclude that inhaled combination fluticasone furoate and 
vilanterol does not affect overall survival or cardiovascular outcomes. 
 
In the previous TORCH trial (9), inhaled combination therapy with salmeterol and 
fluticasone propionate appeared to be associated with a 2·6% absolute reduction (17·5% 
relative risk reduction) in all-cause mortality in patients with moderate-to-severe COPD 
although this fell short of statistical significance (P=0·052). Many of these deaths were 
cardiovascular and a post hoc analysis suggested that the combination treatment might reduce 
cardiovascular mortality (15). In SUMMIT, we tested the hypothesis that greater mortality 
reductions might occur in populations with COPD that are enriched for cardiovascular 
disease. We report that the point estimate for all-cause mortality was 0·7% (12·2% relative 
reduction) lower with combined fluticasone furoate and vilanterol therapy than with placebo. 
This difference was not statistically significant and the trial did not reach its primary end-
point. However, it should be acknowledged that a clinically meaningful difference in 
mortality has not been entirely excluded since the 95% confidence interval for the hazard 
ratio encompasses a 26% reduction in the risk of dying.  
The absence of an effect on overall survival has a number of potential explanations including 
a failure to take sufficient active therapy, inadequate dosing, or a lack of effect on lung 
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function in patients with less severe COPD. However, recorded adherence to treatment was 
high and patients receiving fluticasone furoate experienced expected side effects. As 
anticipated, we observed improvements in FEV1 with both fluticasone furoate and vilanterol 
confirming the efficacy of the two interventions. We therefore do not believe that the failure 
to reach the primary endpoint was due to inadequate dosing or a lack of an effect on COPD. 
Finally, it is interesting to speculate whether more prolonged follow up would have been 
beneficial to increase the number of events, to extend drug exposure, and to acquire a more 
precise point estimate of a potential treatment effect. 
 
We pre-specified the first secondary endpoint as the rate of decline in FEV1 to assess the 
efficacy of the trial intervention on respiratory pathophysiology and disease progression. 
Given the hierarchical analysis plan, these findings should not be viewed as conclusive since 
the primary endpoint was not met. Intriguingly, we did observe that the components appeared 
to have a differential treatment effect on the rate of decline in FEV1. There was a consistent 
reduction in the rate of decline in FEV1 associated with fluticasone furoate-containing arms 
that was not observed with vilanterol. When evaluating the impact of a decrease of 8 mL per 
year, it should be taken into account that in the general population FEV1 normally declines at 
a rate of 25-30 mL per year and that this mean reduction could be viewed as between a third 
and half of the excess decline observed in this study population. In addition, up to half of 
patients with COPD do not experience an accelerated decline suggesting that some patients 
may experience larger effects (18). This observation suggests that medications that include 
inhaled corticosteroids may inhibit lung inflammation and the decline in lung function 
attributable to COPD as noted in much smaller studies of patients with moderate COPD (19). 
This also suggests that treatment of COPD at an earlier stage of the disease process has the 
potential for long-term benefits in preservation of lung function. The beneficial effect of 
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inhaled corticosteroids on FEV1 decline in this study as well as in the TORCH study (20) 
likely reflects the large sample size and power of these studies compared with earlier trials 
(21-24). It is plausible that inhaled corticosteroids could affect decline in lung function 
without having a notable effect on overall mortality given that we only followed study 
participants for slightly less than 2 years, a follow-up period too short to capture a mortality 
benefit in those with only moderate disease. There were fewer moderate and severe 
exacerbations in all treatment arms in SUMMIT supporting a beneficial effect for COPD 
drug treatment, even in patients with milder COPD. 
 
For many clinicians and especially cardiologists, there has been concern about the use of 
inhaled beta-agonists in patients with cardiovascular disease. Some have suggested that 
inhaled beta-agonists are pro-arrhythmic and may precipitate myocardial infarction or sudden 
death (14). In our study, we have intentionally enriched our study population with patients 
who had established, or were at high risk of, cardiovascular disease. Despite this enrichment, 
we detected no evidence of adverse cardiovascular events either self-reported or as 
adjudicated cardiovascular endpoints. The point estimates for all trial interventions were 
favourable and there was no suggestion of an adverse cardiovascular safety signal. We 
believe that the current study highlights the cardiovascular safety of using long-acting beta-
agonists and inhaled corticosteroids in patients with COPD and heightened cardiovascular 
risk. Despite the enrichment for patients with cardiovascular risk, we observed lower rates of 
cardiovascular events than anticipated. This may reflect the high use of highly effective 
preventative treatments, such as antiplatelet, lipid-lowering and renin-angiotensin system 
inhibitor therapies, in our study population. These evidenced-based therapies will 
substantially reduce cardiovascular events and this may have hindered our ability to 
demonstrate a beneficial effect with the study intervention. 
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An increased risk of pneumonia was one of the main findings of the TORCH trial (9, 25) and 
has been found in other studies of inhaled corticosteroids in patients with COPD (26), 
including fluticasone furoate (27). Reassuringly, we observed no such effect in our study. 
Indeed, there were no detectable differences in pneumonia rates between patients receiving 
placebo and those receiving fluticasone furoate alone or in combination with vilanterol. This 
likely reflects the lower rates of pneumonia and the lower rates of bacterial colonisation in 
the airways of patients with milder COPD (28). The apparent lower risk of pneumonia in 
patients receiving vilanterol alone was unanticipated and we do not have a ready explanation 
for this unexpected finding. 
 
In conclusion, in patients with moderate COPD and heightened cardiovascular risk, treatment 
with fluticasone furoate and vilanterol does not affect mortality or cardiovascular outcomes, 
but is associated with fewer exacerbations of COPD and is well tolerated. Fluticasone 
furoate, alone or in combination with vilanterol, appears to reduce the rate of decline in 
FEV1. 
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Table 1  
Baseline characteristics of study participants 
 
 Placebo 
n=4,111 
Fluticasone 
furoate 
n=4,135 
Vilanterol 
n=4,118 
Combination 
therapy 
n=4,121 
Age (year) 65±8 65±8 65±8 65±8 
Female Sex 1040 (25%) 1082 (26%) 1065 (26%) 1009 (24%) 
Race 
 
White  
Asian 
Other 
3328 (81%) 
682 (17%) 
101 (2%) 
3358 (81%) 
683 (17%) 
94 (2%) 
3339 (81%) 
680 (17%) 
99 (2%) 
3332 (81%) 
679 (16%) 
110 (3%) 
BMI (kg/m2) 28±6 28±6 28±6 28±6 
Current Smokers 1936 (47%) 1945 (47%) 1929 (47%) 1868 (45%) 
Smoking History (pack-years)  41±25 41±24 41±24 41±24 
Post-bronchodilator FEV1 (L) 1·70±0·40 1·70±0·41 1·70±0·40 1·70±0·40 
Predicted post-bronchodilator 
FEV1 (%) 
59·7±6·1 59·6±6·1 59·7±6·1 59·7±6·1 
FEV1 reversibility (%)  
(as a percentage of pre-
bronchodilator FEV1) 
8·4±12·1 7·9±11·7 8·3±12·2 8·0±11·8 
Pre-study COPD therapy 
Long-acting beta-agonist 
Long-acting muscarinic-agonist 
 
1417 (34%) 
659 (16%) 
 
1432 (35%) 
619 (15%) 
 
1464 (36%) 
634 (15%) 
 
1456 (35%) 
638 (15%) 
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 Placebo 
n=4,111 
Fluticasone 
furoate 
n=4,135 
Vilanterol 
n=4,118 
Combination 
therapy 
n=4,121 
Inhaled corticosteroid 1349 (33%) 1369 (33%) 1374 (33%) 1394 (34%) 
Pre-study exacerbations in 
12 month prior to study 
 
0 
1 
2+ 
 
2447 (60%) 
1044 (25%) 
620 (15%) 
 
2546 (62%) 
990 (24%) 
599 (14%) 
 
2500 (61%) 
988 (24%) 
630 (15%) 
 
2528 (61%) 
998 (24%) 
595 (14%) 
Cardiovascular inclusion criteriaa 
Manifest disease 
Coronary artery disease 
Peripheral arterial disease 
Previous stroke 
Previous myocardial infarction 
Diabetes with target organ disease 
At risk 
Hypercholesterolaemia 
Hypertension 
Diabetes mellitus 
Peripheral arterial disease 
 
 
2103 (51%) 
766 (19%) 
404 (10%) 
658 (16%) 
374 (9%) 
 
2112 (66%) 
2861 (89%) 
850 (27%) 
279 (9%) 
 
 
2119 (51%) 
755 (18%) 
418 (10%) 
664 (16%) 
355 (9%) 
 
2051 (65%) 
2835 (89%) 
870 (27%) 
264 (8%) 
 
 
2044 (50%) 
817 (20%) 
387 (9%) 
722 (18%) 
377 (9%) 
 
2191 (67%) 
2900 (89%) 
874 (27%) 
301 (9%) 
 
 
2113 (51%) 
807 (20%) 
386 (9%) 
730 (18%) 
397 (10%) 
 
2125 (66%) 
2882 (90%) 
886 (28%) 
310 (10%) 
Baseline Cardiovascular Therapy 
Any medication 
Anti-thrombotic medication 
Lipid Lowering medication 
 
3996 (97%) 
2292 (56%) 
2751 (67%) 
 
4009 (97%) 
2316 (56%) 
2746 (66%) 
 
3996 (97%) 
2295 (56%) 
2797 (68%) 
 
4021 (98%) 
2384 (58%) 
2829 (69%) 
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 Placebo 
n=4,111 
Fluticasone 
furoate 
n=4,135 
Vilanterol 
n=4,118 
Combination 
therapy 
n=4,121 
Renin-angiotensin aldosterone 
inhibitor therapy 
Beta-blockers 
Calcium Channel Blockers 
Nitrates 
Diuretics 
2887 (70%) 
 
1389 (34%) 
1551 (38%) 
613 (15%) 
1508 (37%) 
2841 (69%) 
 
1458 (35%) 
1606 (39%) 
556 (13%) 
1541 (37%) 
2862 (69%) 
 
1376 (33%) 
1569 (38%) 
569 (14%) 
1549 (38%) 
2932 (71%) 
 
1444 (35%) 
1593 (39%) 
556 (13%) 
1550 (38%) 
a. Patients can have multiple cardiovascular diseases or risks at study entry 
Mean±standard deviation, n (%) 
FEV1, forced expiratory volume in one second; COPD, chronic obstructive pulmonary 
disease 
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Table 2 
Reported adverse events among 16,568 patients in the safety population 
 
 Placebo 
n=4,131 
Fluticasone 
furoate 
n=4,157 
Vilanterol 
n=4,140 
Combination 
therapy 
n=4,140 
Any adverse event 2782 (67%) 2820 (68%) 2809 (68%) 2780 (67%) 
Adverse event leading to 
discontinuation of study 
medication 
397 (10%) 367 (9%) 370 (9%) 342 (8%) 
Serious adverse event 918 (22%) 929 (22%) 972 (23%) 961 (23%) 
Fatal adverse event 192 (5%) 183 (4%) 198 (5%) 182 (4%) 
Total exposure to study medication 
(patient-years)  
6614 6889 6955 7038 
Adverse events of special interest: Number of patients (%) and [rate per 100 patient-years]* 
   Local steroid events 146 (4) 
[2·7] 
209 (5) 
[3·9] 
152 (4) 
[2·5] 
225 (5) 
[4·2] 
   All cardiovascular events 695 (17) 
[16·4] 
699 (17) 
[15·7] 
707 (17) 
[15·7] 
735 (18) 
[16·3] 
          Cardiac arrhythmias 211 (5) 
[4·1] 
229 (6) 
[4·1] 
224 (5) 
[3·9] 
209 (5) 
[3·9] 
   Lower Respiratory Tract   226 (5) 238 (6) 220 (5) 221 (5) 
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   Infections excluding pneumonia [4·7] [4·5] [4·2] [4·2] 
   Pneumonia 214 (5) 
[3·8] 
228 (5) 
[4·2] 
163 (4) 
[2·8] 
237 (6) 
[3·9] 
   Hypersensitivity 143 (3) 
[2·6] 
147 (4) 
[2·7] 
160 (4) 
[2·8] 
175 (4) 
[3·0] 
   Bone disorders including 
fractures 
78 (2) 
[1·3] 
79 (2) 
[1·5] 
88 (2) 
[1·6] 
96 (2) 
[1·6] 
   Hyperglycaemia/new onset 
diabetes mellitus 
156 (4) 
[2·7] 
153 (4) 
[2·6] 
134 (3) 
[2·3] 
148 (4) 
[2·3] 
   Corticosteroid-associated eye 
disorder 
43 (1) 
[0·8] 
62 (1)  
[1·0] 
59 (1) 
[1·0] 
57 (1) 
[1·0] 
   Hyper- or hypokalaemia 23 (<1) 
[0·3] 
23 (<1) 
[0·3] 
28 (<1) 
[0·4] 
31 (<1) 
[0·5] 
   Tremor 11 (<1) 
[0·2] 
11 (<1) 
[0·2] 
16 (<1) 
[0·2] 
12 (<1) 
[0·2] 
   Adrenal Suppression 1 (<1) 
[<0·1] 
3 (<1) 
[<0·1] 
0 1 (<1) 
[<0·1] 
 
* Defined as adverse events of interest associated with the known pharmacological action of 
ICS or LABA therapy  
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Table 3 
Primary and secondary outcomes and exacerbations of chronic obstructive pulmonary disease 
 
 Placebo 
 
n=4,111 
Fluticasone 
furoate 
n=4,135 
Vilanterol 
 
n=4,118 
Combination 
therapy 
n=4,121 
All-cause mortality  
P value vs placebo 
275 (6·7%) 251 (6·1%) 
P = 0·284 
265 (6·4%) 
P = 0·655 
246 (6·0%) 
P = 0·137 
Cause-specific mortality     
Cardiovascular  122 97 118 108 
Pulmonary  35 34 33 35 
Cancer  62 59 61 56 
Other  20 21 25 22 
Unknown 36 40 28 25 
Decline in post-
bronchodilator FEV1 
(mL per year) 
Nominal p-value vs placebo* 
46±2·5 38±2·4 
 
 
P = 0·026 
47±2·4 
 
 
P = 0·654 
38±2·4 
 
 
P = 0·019 
First Composite 
Cardiovascular Event 
Nominal p-value vs placebo* 
173 (4·2%) 
 
 
161 (3·9%) 
 
P = 0·317 
180 (4·4%) 
 
P = 0·908 
174 (4·2%) 
 
P = 0·478 
Myocardial Infarction 38 45 44 46 
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 Placebo 
 
n=4,111 
Fluticasone 
furoate 
n=4,135 
Vilanterol 
 
n=4,118 
Combination 
therapy 
n=4,121 
Unstable Angina 26 16 22 19 
Stroke 33 33 30 31 
Transient Ischemic 
Attack 
8 7 12 7 
Sudden Death 62 53 62 63 
Procedural Death 1 1 0 0 
Other Cardiovascular 
Death 
5 6 10 8 
Annual Rate of 
Moderate and Severe 
Exacerbations 
0·35 0·31 0·31 0·25 
Annual Rate of Severe 
Exacerbations 
0·07 0·06 0·06 0·05 
 
n (%), mean± standard error 
FEV1: forced expiratory volume in 1 second;  
* All p-values are versus placebo and are nominal for descriptive purposes only 
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Figure legends: 
 
Figure 1 
Consort diagram describing patient flow through the study. 
 
Figure 2 
Probability of death (primary endpoint) in patients receiving placebo (black), fluticasone 
furoate (orange; FF), vilanterol (green; VI) and combined fluticasone furoate and vilanterol 
(blue; FF/VI) therapy. 
 
Figure 3 
On-treatment rate of decline in forced expiratory volume in one second (FEV1) (B; secondary 
endpoint) in patients receiving placebo (black), fluticasone furoate (orange; FF), vilanterol 
(green; VI) and combined fluticasone furoate and vilanterol (blue; FF/VI) therapy. Error bars 
represent 95% CIs. 
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Figure 1 
 
[1] 1 subject randomised to Placebo in ITT population is assigned to FF/VI, the treatment the subject 
received for the majority of the study, in the safety population. 
[2] Excluded subjects were recruited at sites that were closed due to the result of audit findings or 
other information implying that the integrity of the data had been compromised. 
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Figure 2 
 
 
Figure 3 
 
 
